The AI-powered Viz Subdural Plus reportedly provides automated measurements and labeling of subdural collections, including subdural hemorrhages (SDHs), based on non-contrast CT scans.

Researchers also noted a greater than 30 percent increase in treatment management changes resulting from the use of CT-based adjunctive AI to detect lung metastases in colorectal cancer patients.

Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.

Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.

Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.

Emerging research suggests the use of computed tomography colonography (CTC) in colorectal cancer screening may provide significantly higher preventive benefit at lower costs in comparison to multitarget stool DNA testing.

In a recent interview, Sherry Shen, M.D., discussed the potential impact of FES PET recently being recommended by the National Comprehensive Cancer Network (NCCN) Guidelines for the staging of recurrent or metastatic estrogen receptor-positive (ER+) lobular breast cancer.

Through AI assessment of chest CT scans, the SeleCT Screening may help identify candidates for bronchoscopic lung volume reduction to improve lung function.

Recognizing the daunting combination of increasing imaging volume and workforce shortages, these authors discuss key risk factors contributing to burnout and moral injury in radiology, and potential solutions to help preserve well-being among radiologists.

Refraining from expressing one’s political viewpoints in the workplace needs to be reemphasized.

In a new literature review, researchers discussed key considerations with the use of B-mode ultrasound and contrast-enhanced ultrasound in the detection of hepatocellular carcinoma.

In a recent interview, Samir Abboud, M.D., discussed new research examining the impact of generative AI in maximizing efficiency and reducing the time-consuming nature of radiology reporting.

An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.

Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.

A partial response rate to neoadjuvant chemotherapy on mid-treatment MRI preceded a higher pathologic complete response (pCR) in 61.5 percent of women with triple-negative breast cancer, according to research presented at the American Society of Clinical Oncology (ASCO) conference.

Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.

For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.

The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.

Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.